Attendee search 

Medxense offers accurate continuous glucose monitoring for the intensive care unit (ICU). Normalization of patient blood glucose allows hospitals to reduce mortality and patient length of stay. 

The patented sensor technology platform is the only in the field to offer both high accuracy and near-instantaneous measurements in the hypoglycemic range, necessary for safe normalization of blood glucose.

We are now looking for an investment of 3 MUSD to fund clinical trials in the 2nd half of 2014. Expected exits are trade sale or IPO.

Inveni Capital offers entrepreneurial venture capital to life science companies in Northern and Central Europe.

Inveni Capital, with offices in Helsinki, Finland and Munich, Germany, is a life science focused venture capital firm investing in early to growth stage pharmaceutical development and medical technology companies in Northern and Central Europe. 

Optomeditech Oy develops patent pending breakthrough technology in the field of Intravascular Catheters. The technology uses laser light to aid in placement of the IV catheters, making the process easier, faster, safer and more reliable.

The global IV catheter market is roughly a $2B a year market that is growing 10% a year. Over 30% of first attempts to place IV catheters fail today causing significant costs and discomfort for the patients and caretakers alike. The poor placement of IV catheters is the most common cause of complaints in the hospitals. Optomeditech's product OptiVein has the technology to capture a significant portion of the IV catheter market quickly with the advantages it brings.

Optomeditech Oy has confirmed its regulatory pathway for both its CE mark and 510(k) clearance through presubmission consultation with BSI and FDA respectively and is looking to achieve CE mark by the end of Q1 2014 and 510(k) in the summer of 2014. The company is planning on entering the US market during 2015.

The company is currently conducting a clinical trial at the Helsinki University Hospital in Finland and the results have been very good to date. The clinical trial is scheduled to close at the end of August 2013.

Etteplan provides engineering services and technical product information solutions to the world’s leading companies in the manufacturing industry. Our services are geared to improve the competitiveness of our customers’ products and engineering processes throughout the product life cycle.

Etteplan has a successful in helping customer develop state-of-the-art medical devices. Our services cover the entire development process including regulatory issues and strategies, CE-marking and energy storage related challenges. Etteplan also provides advanced technical product information services such as technical illustrations, user and spare parts manuals.

Fluence Therapeutics is commercializing photodynamic therapy for the treatment of psoriasis and other skin diseases.

We have successfully completed Phase Ia studies and are seeking funding for the completion of a Phase Ib/IIa proof of concept study in Tampere, Finland.

Current therapies are not adequate for the treatment of difficult cases of psoriasis.  Current light therapies use UV light, which is a known carcinogen, requires many treatments and results in premature photoaging.  Systemic pharmaceuticals globally suppress the immune system, resulting in increased rates of infection and certain kinds of cancers. 

Our therapy uses a novel photosensitizer which is activated by harmless red light and, unlike ALA PDT, does not result in pain or residual photosensitivity.  It can treat multiple, large lesions simultaneously.  It is totally inert unless activated by visible red light.  When activated, it preferentially kills activated t cells over other skin cells.